GRO Biosciences closes $60 million Series B financing

Boston, USA-based biotech start-up GRO Biosciences (GRObio) on Friday announced the closing of an oversubscribed $60.3 million Series B financing.

It is nearly four years after GRObio, which is leveraging synthetic biology to expand the amino acid alphabet and deliver on the promise of protein therapeutics, was spun out of George Church’s Harvard Medical School lab.

Proceeds from the financing will be used to advance the company’s lead program into the clinic for the treatment of refractory gout, to broaden the GRObio pipeline, and to expand its genomically recoded organism (GRO) platform for scalable production of therapeutics incorporating multiple non-standard amino acids (NSAAs).